−0.0455USD
−131.00 KUSD
7.79 MUSD
3.70 M
About International Stem Cell Corp.
Sector
Industry
CEO
Andrey Semechkin
Website
Headquarters
San Diego
Employees (FY)
29
Founded
2005
ISIN
US4603782016
FIGI
BBG000BNH2G6
International Stem Cell Corp. operates as a research and development company for the therapeutic market. It focuses on advancing potential clinical applications of human parthenogenetic stem cells for the treatment of various diseases of the central nervous system and liver diseases. The firm operates through three segments: Therapeutic Market, Biomedical Market and Anti-Aging Market. The Biomedical Market segment markets and sells primary human cell research products with two product categories, cells and media. The Anti-Aging market segment markets and sells a line of skincare products sold through two sales channels: ecommerce and professional. The ecommerce channel sells direct to customers through online orders, while professional sales are to spas, salons and other skincare providers. The Therapeutic Market segment focuses on the research and development of human parthenogenetic stem cells for the treatment of diseases of the central nervous system, liver diseases and is currently conducting clinical trials for the treatment of Parkinson's disease. The company was founded by William B. Adams, Kenneth C. Aldrich and Gregory S. Keller in June 2005 and is headquartered in San Diego, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ISCO is 0.0891 USD — it has decreased by 25.76% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange International Stem Cell Corp. stocks are traded under the ticker ISCO.
International Stem Cell Corp. is going to release the next earnings report on May 16, 2024. Keep track of upcoming events with our Earnings Calendar.
Yes, you can track International Stem Cell Corp. financials in yearly and quarterly reports right on TradingView.
Like other stocks, ISCO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade International Stem Cell Corp. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 29.00 employees. See our rating of the largest employees — is International Stem Cell Corp. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. International Stem Cell Corp. EBITDA is −388.00 K USD, and current EBITDA margin is −6.02%. See more stats in International Stem Cell Corp. financial statements.